GLP-1 medications have rapidly gained traction in 2024 as transformative treatments for diabetes and obesity, reshaping the approach to cardiometabolic health. These therapies, recognized for their ability to deliver improved patient outcomes, are poised to play an even greater role in addressing the growing burden of chronic conditions. 

In this Healthcare IT Today article, Avalon’s Dr. Julie Schulz, MD, MPH, alongside industry experts, shares her perspective on the trends fueling this surge and the future potential of GLP-1 drugs.

Read the full article at Healthcare IT Today.